



December 11, 2015

Dear Stockholder,

As we reflect on the past year and look into the coming year, we see a continuous building of momentum. In our fiscal year 2015, our portfolio provided multiple sources of growth that drove us to year-over-year increases in both revenue and profits, and enabled us to expand our addressable market opportunity. We begin fiscal year 2016 with an even broader portfolio that we believe provides improved stability as we manage our way through a downward cycle in the semiconductor business. The Brooks business model has taken full shape and continues to build.

We remain focused on three clear initiatives: to strengthen our position in semiconductor and related markets; shed non-core assets and operations; and accelerate the application of our capabilities to grow our Life Sciences business which we expect will provide an increasing portion of our revenue.

A Year of Growth

The Semiconductor Market Provided a Stage for Demonstrating Our Strengths

As we entered the 2015 fiscal year, the semiconductor market was beginning to percolate with capital projects, and we estimate the equipment market grew approximately 5% over 2014. Although this is reasonable market growth, our Brooks semiconductor revenue grew 15% over the same period. Our exceptional growth is a direct reflection of both the products we have developed to address needs in the high growth sub-segments and the strategic acquisitions we have made. During 2014 we entered the Contamination Control Solutions business through the acquisition of DMS. In 2015, this business provided \$44 million of revenue, well above our original revenue target and a 30% increase when compared to DMS' revenue in 2014 prior to the acquisition.

We delivered a record number of shipments of our market-leading vacuum robots in 2015. We have advanced the capabilities of the product line, secured deeper development partnerships with our OEM customers, and put more distance between us and the rest of the market with our innovative and reliable vacuum products. OEMs have continued to adopt our existing robots to enhance the performance of their legacy systems and are designing their new tools to include our most advanced product set, the Magnatran[®] 9 series robot, which offers increased functionality in a smaller and more serviceable package, which we expect will lead to continued growth from our core strengths in automation.

One of our areas of focus has been the application of automation and cryogenic pumps in the advanced packaging space. As a result of our aggressive product development and early customer contacts, we already have more than 20 customers buying our systems for this space. In 2015, advanced packaging accounted for more than \$30 million of revenue, up 60% from the prior year and, again, demonstrates an expansion of another market opportunity that is on a different cycle than the semiconductor front-end market.

Important Progress in Shedding Non-Core Operations

In the year we also delivered on important milestones to transform our operations. In the first fiscal quarter we closed the Petaluma, California manufacturing site as we ramped up our Polycold manufacturing with a strategic contract manufacturer in Malaysia. This step allowed us to reduce fixed costs and inventory, while locating production closer to our customers. In the Life Sciences business, we executed on our plans to move to contract manufacturing and this allowed us to consolidate operations into a single location. As a result, we significantly reduced our Spokane, Washington footprint, consolidated all of our in-house capabilities in Manchester, England, and then exited our Poway, California manufacturing site in September. These actions leave us with more streamlined operations and significantly lower fixed costs in the Life Sciences business.

Significant Expansion of our Life Sciences Portfolio with Marked Success in R&D and Acquisitions

Frankly speaking, we had a mixed year of revenue results in our Life Sciences business. We saw strong growth in our consumables business, stable progress in services, but a light year of bookings around our storage systems. We have always known that the large sample store bookings are sporadic and in 2015, we saw a protracted period of fewer placements in the industry. Still, we believe that we won more than 70% of the systems that were ordered and we have a pipeline that we expect to provide growth going forward. We remain confident that the large automated store systems provide the foundation of sample management in key commercial and research segments of the market. We are also confident in our pursuit of the broader strategy – to lead the industry to automation and workflow solutions in the sub -150°C segment of biosample management.

We continued a strategic build-out of the business with new offerings from acquisitions and organic product development. On the first day of fiscal 2015, we acquired FluidX, a provider of storage consumables and instruments for ultra-low temperature biosample management. We paid \$15.5 million for this business which subsequently delivered \$15 million of revenue in 2015, a 30% increase over FluidX's 2014 revenue prior to the acquisition, and became accretive to earnings ahead of expectations. We are still in the early stages of ramping up sales capabilities to bring this European-based business to the global markets, and we expect this will help us to expand our addressable opportunity.

In April, we launched a lineup of ultra-cold storage offerings that we expect will redefine the -150°C sample management industry. The BioStore™ III Cryo automated -150°C store applies robotic automation to the industry's leading storage container for bio-samples. This innovation provides customers with dramatic changes in sample preservation, workflow management, sample information, and lab technician safety. 10 Early Adopter customers across a variety of end markets are trying the first units in exchange for feedback that will shape our final product configuration. Meanwhile, we accepted our first commercial orders for the BioStore III Cryo in our fourth fiscal quarter, well ahead of our product plan. In April, we also announced the Cryopod™ Carrier system, the industry's first portable carrier that can protect samples at temperatures below -150°C for more than four hours of safe transport. Complementing this offering is an automated liquid nitrogen charging station, another lab room enhancement to improve workflow and safety. Highlighting the strength of this new product lineup, at the leading sample management industry conference, the Annual Meeting of the International Society of Biological and Environmental Repositories (ISBER), the Cryopod and the BioStore III Cryo automated store won the top two prizes for Best New Products of 2015. These products are redefining the capabilities in the ultra-cold demands of science and we estimate they will expand our market opportunity by \$300 million.

As we begin 2016, we are particularly pleased to be able to expand on our Life Sciences offerings with the addition of BioStorage Technologies, Inc., an Indianapolis-based provider of outsourced services for complete sample management. This acquisition brings a stable, growing, and innovative business into the Brooks portfolio. BioStorage provides services to more than 260 customers, managing steps from collection, transport and logistics, storage, analysis, and disposition of samples. There are some obvious synergy opportunities as BioStorage already manages millions of samples for their customers, primarily in the -80°C and -150°C environment. Many of their customers make use of both outsourced services and in-house storage capabilities.

Our ability to offer a mix of offerings, complete logistics, and integrated information management will yield strong ties with our customers.

Growth in Financial Results

We were proud to report that we finished 2015 with revenue growth of 14%, or \$70 million, above the prior year, supporting an improvement in earnings from continued operations of \$14 million and EPS of \$0.21. We generated \$44 million of cash from operations, which supported \$27 million in dividends paid out to shareholders, an increase of 18% over the prior year.

Looking Forward

As we enter 2016, we feel our business model is stronger than ever. We have once again strengthened our relationships with our expanding customer base, positioned ourselves with leadership offerings in each area of our business, and improved our operational performance. The semiconductor equipment industry is certainly slower as we step into 2016 and during this period we will see lower earnings along with the rest of the industry, but we believe we are better prepared to deal with the cycles than we were in the past. The Life Sciences business has more to offer than ever before and our pipeline is built for a good year. The vitality in our business is evident in all areas.

The Brooks team is proud of our fiscal 2015 results and we see 2016 as a year for additional progress. On behalf of our Board of Directors and the management team here at Brooks, we thank each of our stockholders for their support and confidence, and we look forward to another year of progress in 2016.

Sincerely,



Steve Schwartz
Chief Executive Officer